| Literature DB >> 28017646 |
Sagar Uttarkar1, Jon Frampton2, Karl-Heinz Klempnauer3.
Abstract
The transcription factor Myb is a key regulator of hematopoietic cell proliferation, differentiation, and survival and has been implicated in the development of leukemia and several other human cancers. Pharmacological inhibition of Myb is therefore emerging as a potential therapeutic strategy. Recently, the first low-molecular-weight compounds that show Myb inhibitory activity have been identified. Characterization of these compounds suggests disruption of the protein-protein-interaction of Myb and the coactivator p300 as a suitable strategy to inhibit Myb.Entities:
Mesh：
Substances：
Year: 2016 PMID： 28017646 DOI： 10.1016/j.exphem.2016.12.003
Source DB: PubMed Journal: Exp Hematol ISSN： 0301-472X Impact factor: 3.084